The postchemotherapy PSA surge syndrome.
暂无分享,去创建一个
R de Crevoisier | A Bossi | R. Crevoisier | B. Escudier | R. de Crevoisier | K. Fizazi | C. Massard | A. Bossi | A. Chauchereau | B Escudier | K Fizazi | R Thuret | C Massard | M Gross-Goupil | M Di Palma | A Chauchereau | M. di Palma | R. Thuret | M. Di Palma | M. Gross‐Goupil | B. Escudier | Karim Fizazi | A. Bossi | M. Gross-Goupil | M. D. Palma
[1] J. Pignon,et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.
[2] C. Théodore,et al. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Tomasz Burzykowski,et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[5] I. Tannock,et al. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer , 2005 .
[6] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[7] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[8] S. Culine,et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Eschwège,et al. Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. D'Amico,et al. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Ming-Hui Chen,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.
[12] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[13] D. Hussey. American Society for Therapeutic Radiology and Oncology , 2001 .
[14] A. K. Levinson,et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. , 2000, The Journal of urology.
[15] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A Grünert,et al. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment. , 1999, Urology.
[18] L. Collette,et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. , 1998, British Journal of Cancer.
[19] S. Culine,et al. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. , 1998, American journal of clinical oncology.
[20] R. Arriagada,et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy , 1998, Cancer.
[21] L. Boccon‐Gibod,et al. Clearance of Free and Total Serum PSA after Prostatic Surgery , 1998, European Urology.
[22] Americansocietyfortherapeuticr. Consensus statement: Guidelines for PSA following radiation therapy1 , 1997 .
[23] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Catalona,et al. Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.
[25] W. Fischbach,et al. Neuron‐specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer , 1989 .
[26] J. Holst,et al. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. , 1988, European journal of cancer & clinical oncology.
[27] A. Horwich,et al. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. , 1986, Cancer treatment reports.
[28] N. Yang,et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. , 1985, Cancer research.
[29] A. D'Amico,et al. Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma , 2006, Cancer.
[30] A. Zisman,et al. PSA elevation during prostate cryosurgery and subsequent decline. , 2005, Urologic oncology.
[31] H. Scher,et al. The antiandrogen withdrawal syndrome in relapsed prostate cancer. , 1997, European urology.
[32] S. Fosså,et al. Influence of urological morbidity on quality of life in patients with prostate cancer. , 1997, European urology.